Colorectal Adenomas-Genetics and Searching for New Molecular Screening Biomarkers.

Colorectal most cancers (CRC) is a malignant illness with an incidence of over 1.eight million new instances per 12 months worldwide. CRC end result is carefully associated to the respective stage of CRC and is extra favorable at much less superior phases. Detection of early colorectal adenomas is the important thing to survival.

In spite of applied screening applications displaying effectivity within the detection of early precancerous lesions and CRC in asymptomatic sufferers, a big variety of sufferers are nonetheless recognized in superior phases. 

Research on CRC completed over the last decade has improved our understanding of the etiology and growth of colorectal adenomas and revealed weaknesses within the normal method to their detection and elimination. Recent research search to discover a dependable non-invasive biomarker detectable even within the blood.

New candidate biomarkers could possibly be chosen on the foundation of so-called liquid biopsy, equivalent to lengthy non-coding RNA, microRNA, circulating cell-free DNA, circulating tumor cells, and inflammatory components launched from the adenoma into circulation. In this work, we targeted on each genetic and epigenetic modifications related to the event of colorectal adenomas into colorectal carcinoma and we additionally talk about new doable biomarkers which might be detectable even in adenomas previous to most cancers growth.

Poly(lysine) Dendrimers Form Complexes with siRNA and Provide Its Efficient Uptake by Myeloid Cells: Model Studies for Therapeutic Nucleic Acid Delivery.

The disruption of the cell pathways of protein biosynthesis via the mechanism of RNA interference has been acknowledged as a instrument of good diagnostic and therapeutic significance. However, with a view to completely exploit the potential of this phenomenon, surroundings pleasant and guarded carriers capable of overcoming extra- and intracellular boundaries and delivering siRNA to the purpose cells are wished.

Recently, consideration has centered on the chance of the equipment of multifunctional nanoparticles, dendrimers, as potential provide models for siRNA. The objective of the present work was to guage the formation of dendriplexes using novel poly(lysine) dendrimers (containing lysine and arginine or histidine residues of their development), and to verify the hypothesis that utilizing these polymers might allow an surroundings pleasant strategy of siRNA swap into the cells in vitro to be obtained.

Bovine Type I Telo Collagen Solution 6mg/mL Kit with Neutralization

IBOCLGMO1KIT each
EUR 564
Description: Bovine Type I Telo Collagen Solution 6mg/mL Kit with Neutralization

Rat Tail Type I Telo Collagen Solution 4mg/mL Kit with Neutralization

IRTCLGMB1KIT each
EUR 231
Description: Rat Tail Type I Telo Collagen Solution 4mg/mL Kit with Neutralization

SARS-CoV-2 Neutralization Assay Development Kit (Delta Variant RBD-ACE2)

NTRL-DT-RBD-10 10 x 96-well plates
EUR 2390.76
Description: SARS-CoV-2 Neutralization Assay Development Kit (Delta Variant RBD-ACE2)

SARS-CoV-2 Neutralization Assay Development Kit (Kerala Variant RBD-ACE2)

NTRL-IN-RBD-10 10 x 96-well plates
EUR 2390.76
Description: SARS-CoV-2 Neutralization Assay Development Kit (Indian Variant RBD-ACE2)

SARS-CoV-2 Neutralization Assay Development Kit (Lambda Variant RBD-ACE2)

NTRL-LD-RBD-10 10 x 96-well plates
EUR 2390.76
Description: SARS-CoV-2 Neutralization Assay Development Kit (Lambda Variant RBD-ACE2)

GENLISA™ SARS-CoV-2 (Covid-19) Surrogate Virus Neutralization Test (sVNT) ELISA

KBVH400 12 × 8 wells
EUR 3822

Anti-SARS-CoV-2 Neutralization Antibody Test Kit (Colloidal gold immunoassay)

CP04010 25T/kit Ask for price
Description: The Anti-SARS-CoV-2 Neutralization Antibody Test Kit (Serum/Plasma/Whole blood) is a qualitative membrane-based immunoassay for the detection of SARS-CoV-2 neutralizing antibodies in serum, plasma and whole blood. The sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 neutralizing antibodies in the sample combined with the colloidal gold-labeled SARS-CoV-2 spike protein(SP), then spread to the test area. It is captured by coated SP subunit RBDNTD-CTD, to form a complex and gather in the test area (T line). The quality control area is coated with mouse anti-chicken IgY, and the colloidal goldlabeled chicken IgY is captureed to form a complex and aggregate in hte quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample need to be tested again.

SARS-CoV-2 Neutralization Assay Development Kit (Brazilian Variant RBD-ACE2)

NTRL-BZ-RBD-10 10 x 96-well plates.
EUR 2390.76
Description: SARS-CoV-2 Neutralization Assay Development Kit (Brazilian Variant RBD-ACE2)

SARS-CoV-2 Neutralization Assay Development Kit (Omicron Variant SPIKE-ACE2)

NTRL-OMI-SPIKE-10 10 x 96-well plates
EUR 2390.76
Description: SARS-CoV-2 Neutralization Assay Development Kit (Omicron Variant Spike-ACE2)

SARS-CoV-2 Neutralization Assay Development Kit (South African Variant RBD-ACE2)

NTRL-SA-RBD-10 10 x 96-well plates
EUR 2390.76
Description: SARS-CoV-2 Neutralization Assay Development Kit (South African Variant RBD-ACE2)

SARS-CoV-2 Neutralization Assay Development Kit (South African Variant RBD-ACE2)

NTRL-UK-RBD-10 10 x 96-well plates
EUR 2390.76
Description: SARS-CoV-2 Neutralization Assay Development Kit (United Kingdom Variant RBD-ACE2)

Anti-SARS-CoV-2 Neutralization Antibody Test Kit (Enzyme-linked immunosorbent assay)

CP04012 96T/5*96T Ask for price
Description: It is a semi quantitative competition ELISA kit to detect the Anti-SARS-CoV-2 Neutralization Antibody in human serum or plasma. The micro test plate provided in this kit is pre-coated with recombinant human ACE2. During the reaction, the SARS-CoV-2 neutralization antibody in the standard & sample diluent pretreated samples or controls competes with a fixed amount of human ACE2 on the solid phase supporter for sites on the Horseradish peroxidase (HRP) conjugated recombinant SARS-CoV-2 RBD fragment (HRP-RBD). After 37℃incubation, the unbound HRP-RBD as well as any HRP-RBD bound to non-neutralization antibody will be captured on the plate and eventually form the ACE2-RBD-HRP complex, while the circulating neutralization antibodies HRP-RBD complexes remain in the supernatant and are removed during washing. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color change is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm.

Neutralizing Buffer 100gm

236210 EACH
EUR 85.2

Sputum Neutralising Buffer (Phenol Red)

RRSP2247-D 500ml
EUR 12.49

Sodium Hydroxide 4% (Sputum Neutralising Buffer)

RRSP2246-D 500ml
EUR 12.49

Formalin, 10% neutral buffered (phosphate buffer)

08379-20 20L
EUR 384
Description: 50-00-0

Formalin, 10% neutral buffered (phosphate buffer)

08379-3.75 3,75L
EUR 160
Description: 50-00-0

Swab-Sampler with Neutral Buffer

FSA1188 PK100
EUR 121.2

10%-Formaldehyde Neutral Buffer Solution

37152-51 1L
EUR 16.8

10%-Formaldehyde Neutral Buffer Solution

37152-64 10L
EUR 70

Premoistened in Neutra Buffer

SWA1002 PK250
EUR 121.2

Premoistened in Neutra Buffer BL

SWA1004 PK250
EUR 122.4

10% Neutral Buffered Formalin

NBF105 5L
EUR 142.8

Formalin (10% Neutral Buffered)

FRN125 125 ml
EUR 73.2

Formalin (10% Neutral Buffered)

FRN3800 1 Gal.
EUR 144

Formalin (10% Neutral Buffered)

FRN500 500 ml
EUR 79.2

Formalin (10% Neutral Buffered)

FRN999 1000 ml
EUR 100.8

10% Neutral Buffered Formalin 1.75L in 5L PAIL

NBF5175 EACH
EUR 12.54

Formalin, 10% Neutral Buffered, 1 gallon

28600-1 -
EUR 68

10% Neutral Buffered Formalin 120mL in 250mL PAIL

NBF250M EACH
EUR 3.42

Formalin, 10% solution, neutral buffered

GE0900-1 1
EUR 22.7

Formalin, 10% solution, neutral buffered

GE0900-2500 2500
EUR 45.2

Formalin, 10% solution, neutral buffered with 0.03% Eosin

GE0227-1 1
EUR 22.7

Formalin, 10% solution, neutral buffered with 0.03% Eosin

GE0227-2500 2500
EUR 45.2

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody

abx411283-02mg 0.2 mg
EUR 678

D E Neutralizing Bt 500gm

281910 EACH
EUR 211.2

D/E NEUTRALIZING AGAR

D04-112-10kg 10 kg
EUR 1843.2

D/E NEUTRALIZING AGAR

D04-112-2Kg 2 Kg
EUR 447.6

D/E NEUTRALIZING AGAR

D04-112-500g 500 g
EUR 165.6

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody (FITC)

abx411284-01mg 0.1 mg
EUR 610.8

Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)

BCA-M43 100ug
EUR 2354
Description: Anti-BCMA Neutralizing Antibody, is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with BCMA.

D/E NEUTRALIZING BROTH

D04-115-10kg 10 kg
EUR 1210.8

D/E NEUTRALIZING BROTH

D04-115-2kg 2kg
EUR 309.6

D/E NEUTRALIZING BROTH

D04-115-500g 500 g
EUR 128.4

D/E Neutralizing Broth

MED1144 PK50
EUR 60

Neutralizing Solution

10750014-1 1 L
EUR 42.29

DNA NEUTRALIZING SOLUTION

D544 1000ML
EUR 26.84

human anti-CPV neutralizing mAb

E4A09V04 50ug
EUR 255
Description: Available in various conjugation types.

human anti-FPV neutralizing mAb

E4A09V05 50ug
EUR 255
Description: Available in various conjugation types.

human anti-FPV/CPV neutralizing mAb

E409C40-h100 100μL
EUR 395
Description: Available in various conjugation types.

Anti-PD-1 Neutralizing Antibody

71120 100 µg
EUR 465
Description: Neutralizing recombinant murine/human chimeric antibody recognizing the PD-L1/PD-L2 binding region of human PD-1. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Anti-BTLA Neutralizing Antibody

100244 100 µg
EUR 355
Description: This anti-BTLA antibody is a purified recombinant human monoclonal antibody which recognizes the human BTLA protein. BTLA (B- and T-lymphocyte attenuator) belongs to the CD28 immunoglobulin superfamily (IgSF) and is an immune-regulatory receptor that binds to HVEM (Herpesvirus entry mediator, also known as TNFRSF14, Tumor necrosis factor receptor superfamily member 14). This antibody has been tested for specific binding to purified human BTLA protein and neutralizes the interaction between BTLA and HVEM.

Anti-VEGF Neutralizing Antibody

79478-1 50 µg
EUR 355
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species.

Anti-VEGF Neutralizing Antibody

79478-2 100 g
EUR 460
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species.

Anti-LAG3, Neutralizing Antibody

71219 100 µg
EUR 530
Description: Neutralizing recombinant human antibody recognizing the Lag-3 binding region.

Rabbit anti-LukAB pAb (neutralizing)

0313-001 500ug
EUR 486
Description:
  • Related to: Staphylococcus
  • Applications: Neutralization

Anti-VISTA Neutralizing Antibody

101293 100 µg
EUR 450
Description: This human monoclonal antibody recognizes human V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA), and neutralizes its interaction with VSIG3 (also called IGSF11). VISTA is also known as B7-H5 or VSIR (GenBank Accession No. NM_022153). VSIG3 is a ligand involved in cell adhesion as a VISTA binding partner. This neutralizing antibody has been functionally tested using the VSIG-3:VISTA [Biotinylated] Inhibitor Screening Assay Kit (BPS Bioscience #79782).

Anti-RANKL Neutralizing Antibody

100874-1 50 µg
EUR 335
Description: Human, recombinant monoclonal antibody recognizing the RANKL protein, also known as TNFSF11 antibody and CD254 antibody. This antibody recognizes human RANKL. It has not been tested with other species. MW= 50 kDa (Heavy chain); 24 kDa (Light chain).

Anti-RANKL Neutralizing Antibody

100874-2 100 µg
EUR 460
Description: Human, recombinant monoclonal antibody recognizing the RANKL protein, also known as TNFSF11 antibody and CD254 antibody. This antibody recognizes human RANKL. It has not been tested with other species. MW= 50 kDa (Heavy chain); 24 kDa (Light chain).

Anti-PCSK9 Neutralizing Antibody

71207 50 µg
EUR 555
Description: Neutralizing recombinant human antibody (IgG1) recognizing the LDLR binding region of human PCSK9.

Anti-TIGIT Neutralizing Antibody

71340 100 µg
EUR 565
Description: Human Anti-TIGIT neutralizing antibody recognizing the TIGIT binding region on immune cells.

Anti-IL-17A Neutralizing Antibody

91015 100 µg
EUR 490
Description: Neutralizing recombinant human_x000D_chimeric antibody recognizing human IL-17A._x000D_This antibody has not been tested for crossreactivity_x000D_with other species.

Anti-PD-L1 (CD274) Neutralizing Antibody

71213 100 µg
EUR 505
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested.

Anti-CTLA4 (CD152) Neutralizing Antibody

71212 100 µg
EUR 490
Description: Neutralizing recombinant human monoclonal antibody recognizing the extracellular domain of CTLA4 and blocking binding of CTLA4 to B7.1 and B7.2. This antibody recognizes human CTLA4 but does not bind to murine CTLA4. This antibody has not been tested for cross-reactivity with other species.

Anti-β-Amyloid Neutralizing Antibody

71223 100 µg
EUR 465
Description: Purified, recombinant, humanized Anti-β-amyloid (IgG1) antibody, expressed in HEK293 cells. This antibody reacts with human β-amyloid and has not been tested for cross-reactivity with other species.

Interferon alpha Neutralizing Antibody

20-abx137013
  • EUR 427.20
  • EUR 627.60
  • 0.5 mg
  • 1 mg

Anti-COVID-19 S-IgM Neutralizing Antibody

E38A9973 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-IgA Neutralizing Antibody

E38A9974 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Horse Anti-Rabies Virus IgG (Fab2), neutralizing

RBV16-Fab2 100 ul
EUR 534

Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-2)

100792 100 µg
EUR 460
Description: Recombinant human monoclonal (clone 414-2) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-1)

100793 100 µg
EUR 485
Description: Recombinant human monoclonal (clone 414-1) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Bovine Type I Collagen Neutralized Solution 5mg/mL

IBOCLGMI35ML each
EUR 468
Description: Bovine Type I Collagen Neutralized Solution 5mg/mL

Anti-COVID-19 S-hIgG1 Neutralizing Antibody

E38A9970 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-mIgG1 Neutralizing Antibody

E38A9971 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-cIgG1 Neutralizing Antibody

E38A9972 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-2019-nCoV S-IgM Neutralizing Antibody (8A5)

EPT006 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-IgA Neutralizing Antibody (8A5)

EPT018 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-hIgG1 Neutralizing Antibody (8A5)

EPT031 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-mIgG1 Neutralizing Antibody (8A5)

EPT084 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-cIgG1 Neutralizing Antibody (8A5)

EPT085 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-NGF (Nerve Growth Factor) Neutralizing Antibody

100436-1 50 µg
EUR 355
Description: Anti-NGF Neutralizing Recombinant Human antibody. This_x000D_ antibody has not been tested for crossreactivity_x000D_ with other species.

Anti-NGF (Nerve Growth Factor) Neutralizing Antibody

100436-2 100 µg
EUR 490
Description: Anti-NGF Neutralizing Recombinant Human antibody. This_x000D_ antibody has not been tested for crossreactivity_x000D_ with other species.

Spike Neutralizing Antibody (Clone G10xA1) (SARS-CoV-2)

101326 100 µg
EUR 600
Description: This monoclonal antibody recognizes the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2 [Table of Variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using the Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2):ACE2 Inhibitor Screening Colorimetric Assay Kit (BPS Bioscience #78339).

Spike Neutralizing Antibody (Clone G10xA5) (SARS-CoV-2)

101327 100 µg
EUR 600
Description: This monoclonal antibody recognizes the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2 [Table of Variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using the Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit (BPS Bioscience, #78339).

Anti-PD-1 Neutralizing Antibody, Biotin-labeled

71215 100 µg
EUR 510
Description: Purified, recombinant, human anti-PD-1 (IgG1) antibody with C-terminal Avitag, expressed in HEK293 cells. Purified antibody was enzymatically biotinylated using Avitag™ technology. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Mouse anti-COVID-19 S-mIgG1 Neutralizing Antibody

DL99726A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Mouse anti-COVID-19 S-mIgG1 Neutralizing Antibody

DL99726A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Spike Neutralizing Antibody (Clone LxC1-G10) (SARS-CoV-2)

101246 100 µg
EUR 545
Description: This human monoclonal antibody recognizes SARS-CoV-2 full-length spike proteins in the native trimeric conformation. This antibody cross-reacts with the wildtype (BPS Bioscience #100728) as well as the Alpha B.1.1.7 (BPS Bioscience #510334), Beta B.1.351 (BPS Bioscience #510333), Beta B.1.351Δ242-244 (BPS Bioscience #101091), Gamma P.1 (BPS Bioscience #100989), Delta B.1.617.2 (BPS Bioscience #101147) and Delta Plus B.1.617.2.1 (BPS Bioscience #101165) variant spike trimers [Table of variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike Trimer: ACE2 Inhibitor Screening Kits (available for purchase).

Anti-PD-L1 Neutralizing Antibody, Biotin-labeled

71214 100 µg
EUR 510
Description: Purified, recombinant, chimeric murine/human anti-PD-L1 (IgG1) antibody with C-terminal Avi-tag, expressed in HEK293 cells. Purified antibody was enzymatically biotinylated using Avitag™ technology. This antibody reacts with human PD-L1 and cross-reacts with mouse PD-L1. It has not been tested for cross-reactivity with other species.

Human-anti-SARS-CoV-2-antibody(Neutralizing)

E28F04204 N/A
EUR 1777.78
Description: N/A

Human Cells anti-COVID-19 S-IgM Neutralizing Antibody

DL99728A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgM Neutralizing Antibody

DL99728A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgA Neutralizing Antibody

DL99729A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgA Neutralizing Antibody

DL99729A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

SARS-CoV-2 Neutralizing Monoclonal Antibody [DA0002]

A73683-100 100 ul
EUR 506

Monoclonal NGF/proNGF Neutralizing Antibody Antibody

AMM06679G 0.05mg
EUR 633.6
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E

SeroFlash SARS-CoV-2 Neutralizing Antibody Assay Fast Kit

D-1008
  • EUR 359.70
  • EUR 570.90
  • 48 Assays
  • 96 Assays

Human Cells anti-COVID-19 S-hIgG1 Neutralizing Antibody

DL99725A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-hIgG1 Neutralizing Antibody

DL99725A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

GENLISA SARS-CoV-2 (Covid-19) Mu Neutralizing Antibody (B.1.621) ELISA

KBVH490 1 x 96 wells
EUR 665.5

Spike S1 Neutralizing Antibody (WT, B.1.1.7 and B.1.351 Variant) (Clone C-A11) (SARS-CoV-2)

101024 100 µg
EUR 585
Description: This purified rabbit monoclonal antibody recognizes recombinant wildtype SARS-CoV-2 Spike RBD and trimeric spike proteins. Additionally, this antibody cross-reacts with the B.1.1.7 variant, originally discovered in the U.K, and the B.1.351 variant, originally discovered in South Africa, for both the Spike RBD and trimeric proteins. This neutralizing antibody impedes the interaction between SARS-CoV-2 spike proteins and ACE2 receptor. ACE2 receptor is known to mediate COVID-19 infection through direct binding of the SARS-CoV2 Spike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (BPS Bioscience, #78018, #78133, #78152). This antibody not been tested for cross reactivity with other SARS-CoV-2 variants.

Anti-PCSK9 Neutralizing Antibody, (IgG1) Biotin-labeled

71216 50 µg
EUR 530
Description: Purified recombinant human_x000D_anti-PCSK9 (IgG1) antibody with a C-terminal_x000D_Avi-tag, expressed in HEK293 cells. Purified_x000D_antibody was enzymatically biotinylated using_x000D_AviTag™ technology. This antibody reacts with_x000D_human PCSK9 and has not been tested for_x000D_cross-reactivity with other species.

Anti-PCSK9 Neutralizing Antibody, (IgG4) Biotin-labeled

71217 50 µg
EUR 515
Description: Purified recombinant human_x000D_anti-PCSK9 (IgG4) antibody with a C-terminal_x000D_Avi-tag, expressed in HEK293 cells. Purified_x000D_antibody was enzymatically biotinylated using_x000D_AviTag™ technology. This protein reacts with_x000D_human PCSK9 and has not been tested for_x000D_cross-reactivity with other species.

Spike S1 Neutralizing Antibody (VHH), Fc-fusion (IgG1), Avi-Tag (SARS-CoV)

100784 100 µg
EUR 595
Description: SARS-CoV monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag™ fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. VHHs are single-domain antibodies from camelids.

Cynomolgus anti-COVID-19 S-cIgG1 Neutralizing Antibody

DL99727A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Cynomolgus anti-COVID-19 S-cIgG1 Neutralizing Antibody

DL99727A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

GENLISA SARS-CoV-2 (Covid-19) Beta Neutralizing Antibody (B.1.351, B.1.351.2,B.1.351.3) ELISA

KBVH420 1 x 96 wells
EUR 665.5

GENLISA SARS-CoV-2 (Covid-19) Iota Neutralizing Antibody (B.1.526) ELISA

KBVH460 1 x 96 wells
EUR 665.5

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)

SAD-S35 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

Classical Porcine Fever Virus Neutralizing Antibody ELISA Kit

RK04111 96T
EUR 625.2

GENLISA SARS-CoV-2 (Covid-19) Alpha Neutralizing Antibody (B.1.1.7) ELISA

KBVH410 1 x 96 wells
EUR 665.5

GENLISA SARS-CoV-2 (Covid-19) Gamma Neutralizing Antibody (P.1,P.1.1,P.1.2) ELISA

KBVH450 1 x 96 wells
EUR 665.5

GENLISA SARS-CoV-2 (Covid-19) Kappa Neutralizing Antibody (B.1.617.2) ELISA

KBVH470 1 x 96 wells
EUR 665.5

OAAQ00225-20UL - SARS-CoV-2 Spike S1 (C-A11) Neutralizing Antibody

OAAQ00225-20UL 20uL
EUR 200

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122)

SCT-M369 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Mouse IgG1 (AM122) (SCT-M369), originally from mouse immunized with recombinant SARS-CoV-2 Spike RBD protein, is recombinantly expressed from HEK293 cells.

Cytomegalovirus gH Late Neutralizing Antigen (CMV-LA gH) Antibody

abx411285-02mg 0.2 mg
EUR 678

GENLISA SARS-CoV-2 (Covid-19) Lambda Neutralizing Antibody (C.37) ELISA

KBVH480 1 x 96 wells
EUR 665.5

OAAQ00225-200UL - SARS-CoV-2 Spike S1 (C-A11) Neutralizing Antibody

OAAQ00225-200UL 200uL
EUR 540

Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180)

SPD-M180 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 0.98 μg/mL using SARS-CoV-2 Inhibitor Screening Kit (Cat. No. EP-105).Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

GENLISA SARS-CoV-2 (Covid-19) Epsilon Neutralizing Antibody (B.1.429,B.1.427) ELISA

KBVH440 1 x 96 wells
EUR 665.5

GENLISA SARS-CoV-2 (Covid-19) Omicron Neutralizing Antibody (B.1.1.529) ELISA

KBVH520 1 x 96 wells
EUR 665.5

Goat Anti-Human Respiratory Syncytial Virus (RSV) IgG, neutralizing

RSV12-S 100 ul
EUR 548.4

Anti-SARS-CoV-2 (B.1.351) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

RAS-N031 96tests
EUR 706.2
Description: It's been reported that coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 (B.1.617.2) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

RAS-N040 96tests
EUR 706.2
Description: Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. As concerns over the potential impacts of the variants grow, people ask if one possesses protective neutralizing antibodies (NAbs) against the variants after receiving the currently available vaccines; and if the NAb therapeutic agents are equally effective to treat the mutant infection as the wild type. To facilitate the mutant-related research, drug trials and vaccine assessments, a high-throughput assay to measure neutralizing antibodies against the mutants is in urgent need.

Anti-SARS-CoV-2 (B.1.1.529) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

RAS-N056 96tests
EUR 706.2
Description: As of Nov 29th, confirmed cases of a new variant of concern (VOC) B.1.1.529 have been reported in South Africa, Botswana and more than 12 other countries. Thanks to the rapid sequencing efforts of South African scientists, the whole world is now alerted about this potentially devastating lineage, which was assigned the name Omicron by WHO.Omicron is a highly divergent variant with a high number of mutations (26-35) in the spike. Identification of some familiar mutations that also appeared on other VOCs gives rises to concerns of its immune escape potential and higher transmissibility. To facilitate the mutant-related research, drug trials and vaccine development, a high-throughput assay to measure neutralizing antibodies against the mutants is in urgent need.

Spike Trimer Neutralizing Antibody (B.1.617.2, B.1.617.2.1, WT and B.1.1.7 Variants) (Clone hC-A11) (SARS-CoV-2)

101061 100 µg
EUR 475
Description: This antibody is a humanized monoclonal antibody which recognizes SARS-CoV-2 spike RBD and the full-length spike proteins in the native trimeric conformation. This antibody is derived from rabbit monoclonal C-A11 neutralizing antibody (BPS Bioscience, #101024). It cross-reacts with the wildtype as well as the B.1.617.2 (Delta Variant), B.1.617.2.1 (Delta PLUS Variant), B.1.1.7 (Alpha Variant) RBDs and spike protein trimers [See Table of variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Sike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits (available for purchase).

Mouse Monoclonal Anti-HIV-1 gp120 (PND, principal neutralizing domain) IgG

AB-15110 100 ug
EUR 416.4

NOVATest VAPERON Neutralizing Antibody Rapid Detection Kit (NOVA Test)

COVNA-503 20 Tests Ask for price

Rabbit monoclonal Anti-MERS Spike protein (S1/RBD/MERS-RBD) IgG (Neutralizing)

MERS122-M 100 ul
EUR 781.2

Mouse monoclonal Anti-MERS Spike protein RBD (MES-RBD) IgG1 (neutralizing)

MERS125-M 100 ul
EUR 578.4

Anti-SARS-CoV-2 (B.1.617.2) Neutralizing Antibody Titer Serologic Assay Kit (Spike Trimer)

RAS-N041 96tests
EUR 706.2
Description: Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. As concerns over the potential impacts of the variants grow, people ask if one possesses protective neutralizing antibodies (NAbs) against the variants after receiving the currently available vaccines; and if the NAb therapeutic agents are equally effective to treat the mutant infection as the wild type. To facilitate the mutant-related research, drug trials and vaccine assessments, a high-throughput assay to measure neutralizing antibodies against the mutants is in urgent need.

Rabbit Anti-Poliomyelitis Virus 1 (LSc,2ab strain) antiserum, neutralizing

POLV16-S 100 ul
EUR 548.4

GENLISA SARS-CoV-2 (Covid-19) Delta/DeltaPlus Neutralizing Antibody (B.1.617.2, AY.1,AY.2) ELISA

KBVH430 1 x 96 wells
EUR 665.5

GENLISA SARS-CoV-2 (Covid-19) Neutralizing Antibody S1 mutation D614G ELISA

KBVH500 1 x 96 wells
EUR 665.5

GENLISA SARS-CoV-2 (Covid-19) Omicron Neutralizing Antibody [S1+S2 Trimer] (B.1.1.529) ELISA

KBVH510 1 x 96 wells
EUR 665.5

Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

RAS-N022 96tests
EUR 631.3
Description: It's been reported that coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 (B.1.1.7) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

RAS-N028 96tests
EUR 706.2
Description: It's been reported that coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 (P.1) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

RAS-N034 96tests
EUR 706.2
Description: It's been reported that coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-SARS-CoV-2 (BA.2) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

RAS-N087 96tests
EUR 706.2
Description: A more contagious subvariant of omicron, known as BA.2, is spreading across the globe and could soon become the dominant version of Covid-19.It's now the top variant in at least 18 countries and rapidly spreading, representing 35% of all new cases that have been genetically sequenced worldwide, up from 10 countries and 21% of cases the week before, according to new data from the World Health Organization. In the U.S, BA.2 currently makes up 3.8% of genetically sequenced Covid cases, according to the Centers for Disease Control and Prevention.To facilitate the mutant-related research, drug trials and vaccine development, a high-throughput assay to measure neutralizing antibodies against the mutants is in urgent need.

Anti-SARS-CoV-2 (BA.4 & BA.5) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

RAS-N107 96tests
EUR 706.2
Description: The newly identified 2019 novel coronavirus (SARS-CoV-2) has posed a serious threat to human health, and it spreads quickly. It is helpful to develop the Anti SARS-CoV-2 neutralizing antibody titer serologic assay kit to test the protective neutralizing antibody level in serum.

Anti-SARS-CoV-2 (BA.2.12.1) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

RAS-N120 96tests
EUR 706.2
Description: The newly identified 2019 novel coronavirus (SARS-CoV-2) has posed a serious threat to human health, and it spreads quickly. It is helpful to develop the Anti SARS-CoV-2 neutralizing antibody titer serologic assay kit to test the protective neutralizing antibody level in serum.

Anti-Bevacizumab Antibody (AY12) (recommended for neutralizing assay)

BEB-Y12 100ug
EUR 2354
Description: Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Bevacizumab F(ab')2.

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122)

S1N-M122 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein. As verified in competitive ELISA-based and pseudovirus-based neutralization assay, this chimeric monoclonal can potently neutralize all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529).

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122)

SPD-M162 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293).

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgA1 (AM122)

SPD-M58P1 100ug
EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgA1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgA1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein.

PE-Labeled Human PD-1 / PDCD1 Protein, Fc,His Tag (recommended for neutralizing assay)

PD1-HP2F2 50tests
EUR 1134.2
Description: PE-Labeled Human PD-1, Fc,His Tag (Cat. No. PD1-HP2F2) is produced via site-specific conjugation of PE to Human PD-1, Fc,His Tag under optimal conditions with a proprietary technology. Human PD-1, Fc,His Tag is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # Q15116-1).

Human Monoclonal Anti-Chikungunya virus (CHIKV) E1_E2 protein IgG1 (neutralizing)

CHIKE13-M 100 ul
EUR 578.4

Rabbit Anti-Poliomyelitis Virus 2 (P712,Ch,2ab strain) antiserum, neutralizing

POLV22-S 100 ul
EUR 548.4

G. Pig anti-Poliomyelitis Virus 2 (sabin strain, native) antiserum, neutralizing

POLV23-S 100 ul
EUR 548.4

Rabbit Anti-Poliomyelitis Virus 3 (Leon1,Ch,2ab strain) antiserum, neutralizing

POLV32-S 100 ul
EUR 548.4

G. Pig anti-Poliomyelitis Virus 3 (sabin strain, native) antiserum, neutralizing

POLV33-S 100 ul
EUR 548.4

Mouse monoclona Anti-Rabies Virus Glycoprotein (RVG) IgG, neutralizing (clone 1)

RBVGP12-M 100 ul
EUR 578.4

Mouse monoclona Anti-Rabies Virus Glycoprotein (RVG) IgG, neutralizing (clone 2)

RBVGP13-M 100 ul
EUR 578.4

Horse Anti-C. tetani purified toxin/Toxoid IgG (Tetanus antitoxin, neutralizing, 300 IU/ml)

TTOX18-A 100 ul
EUR 578.4

Horse Anti-C. tetani purified toxin/Toxoid IgG (Tetanus antitoxin, neutralizing, 750 IU/ml)

TTOX19-A 100 ul
EUR 578.4

The fluorescence polarization analysis, along with zeta potential and hydrodynamic diameter measurements have been used to characterize the dendrimer:siRNA complexes. The cytotoxicity of dendrimers and dendriplexes was evaluated with the resazurin-based assay. Using the motion cytometry methodology, the effectivity of siRNA transport to the myeloid cells was determined.

This methodology allowed us to seek out out the properties and optimum molar ratios of dendrimer:siRNA complexes, along with to show that poly(lysine) dendrimers might perform surroundings pleasant carriers of genetic supplies, being far more environment friendly than the commercially obtainable transfection agent Lipofectamine 2000. This ultimate consequence provides the basis for added evaluation on the equipment of poly(lysine) dendrimers as carriers for nucleic acids throughout the topic of gene treatment.